Blocking antibodies targeting galectin-9 can overcome this limitation and suppress tumor growth in combination with chemotherapy in a breast cancer mouse model66, and in ex vivo models of follicular lymphoma67. The gene discussed is LGALS9; the disease is breast carcinoma.